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1.  INTRODUCTION
A recent outbreak of the global pandemic coronavirus 
disease 2019 (COVID-19) caused by a deadly virus named 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has offered extreme health threats extending the plight 
of human survival1-2. The stark reality comes with global death 
toll crossing 4,00,857, with 69,31,000 laboratory-confirmed 
positive cases by June 8, 2020 and the toll is climbing day 
by day3. This unprecedented event of rapid disease spread 
and fatality all over the globe have forced many countries to 
initiate prudent decision of complete lockdown for reducing 
the rate of infection and subsequent deaths. Presently, the 
global case fatality rate is around 4% which is varying in 
different countries4. The World Health Organisation (WHO) 
could not lensed to recommend any antiviral medicine and 
vaccine candidate for the prevention and treatment of this 
disease to date. Therefore, the scientists, clinicians, and all 
other researchers are desperately working towards inventing 
the potential antiviral components against SARS-CoV-2.
Several phytochemicals and natural products showed 
antiviral properties during the previous two coronavirus 
outbreaks (SARS-CoV in 2013 and MERS-CoV in 2012), 
influenza virus-induced seasonal epidemics and against dengue 
virus5-6. It was reported that preventive antiviral therapies 
with phytochemicals and other drugs like chloroquine, 
hydroxychloroquine, azithromycin, lopinavir/ritonavir, 
remdesivir, flavipiravir, teicoplanin , etc. for management 
of COVID-197. However, the roadmaps to get full proof of 
experimental results of the clinical trials for effective COVID-
19 treatment are still under process. Therefore, the prediction of 
potential inhibitors and target molecules to COVID-19 with a 
structure-based computational approach is urgently required to 
rebuild human lives and survival. To achieve this, several studies 
have been initiated in recent time to examine the potential of 
numerous botanical secondary metabolites in inhibiting SARS-
CoV-2 target molecules which need further investigations 
for the development of successful drug8. Among these viral 
proteins, the spike glycoprotein, main protease, papain-like 
protease, and RNA-dependent RNA polymerase play crucial 
role in viral entry, attachment, processing, replication, and 
transcription that cause cellular damage and death. However, 
the in-silico inhibitory potential of phytoligands against these 
prime viral proteins remains to be investigated with detail to 
date. Authors hypothesis was to predict whether these botanical 
natural products could be effective against COVID-19 and how 
these might provide the opportunity to develop prophylactic or 
therapeutic strategies to combat this pandemic.
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Hence, authors aimed to study the role of antiviral 
phytoligands from the commonly available traditional 
botanical resources against SARS-CoV-2 which could lead to 
the discovery of future prophylactics and therapeutic strategies 
for management of COVID-19 and related unshielded 
expenses viral diseases. Recent reports from our group showed 
the medicinal and therapeutic properties of botanical resources 
from different phytogeographical regions of India which could 
be used as a prophylactic and therapeutic agent against various 
human maladies including viral diseases like COVID-199-11. 
In the present study, several phytoligands found abundantly 
in various medicinal plants were selected after extensive 
literature review, rigorous screening of major databases, 
and ethnopharmacological claims12. Authors aimed towards 
identifying novel phytoligands from widely available botanical 
resources by the computational approach which could serve 
as potential inhibitors against the antiviral targets of SARS-
CoV-2. 
To achieve this, authors looked at the absorption, 
distribution, metabolism, excretion, and toxicity (ADMET) 
properties, molecular docking based binding affinities, 
and protein-ligand interaction profile of virtually screened 
phytoligands and few recommended synthetic repurposing 
drugs against SARS-CoV-2 spike glycoprotein, main protease, 
papain-like protease, and RNA-dependent RNA polymerase. 
Finally, we proceed to examine which phytoligand(s) could 
serve as specific as well as broad-spectrum inhibitor(s) against 
these most significant antiviral targets and to provide the 
foundation of drug discovery. The high degree of positive 
results coupled with these phytoligands from the common 
medicinal plants could provide novel, affordable, and safe drug 
or natural prophylactic against the newly emerging and highly 
contagious COVID-19. 
2. MATERIALS AND METHODS
2.1 Data Mining for Phytoligands and Viral 
Proteins
Antiviral phytoligands from very common plant resources 
having various traditional uses in the Indian subcontinent were 
screened from various databases such as Indian Medicinal 
Plants, Phytochemistry And Therapeutics (IMPPAT)13; ZINC 
database14; Traditional Knowledge Digital Library (TKDL) 
(http://www.tkdl.res.in); Dr Duke’s Phytochemical and 
Ethnobotanical Databases (https://phytochem.nal.usda.gov/
phytochem/search/list); Pubchem (https://pubchemdocs.
ncbi.nlm.nih.gov/covid-19); and DrugBank (https://www.
drugbank.ca/covid-19, https://www.drugbank.ca/categories/
DBCAT000066). Initially, from 14532 potential compounds, 
a total of 55 phytoligands were selected after rigorous 
screening based on ADMET properties and drug-likeness, 
literature survey, and traditional botanical knowledge with 
wide availability in the Indian subcontinent. We also included 
8 commonly recommended synthetic antiviral drug candidates 
which are being tested against SARS-CoV-2 as the control for 
this study. 
The three-dimensional (3D) structures of all phytoligands 
were retrieved from Pubchem (https://pubchem.ncbi.nlm.nih.
gov/) and DrugBank (https://www.drugbank.ca/covid-19) in 
structured data format (SDf) and Protein data bank (PDB) 
formats, respectively. The phytoligands were then converted 
into PDB format from SDf format by OPENBABEL 
(http://www.vcclab.org/lab/babel/). The crystal structures 
of SARS-CoV-2 spike glycoprotein (PDB: 6VyB)15, main 
protease (PDB: 6y2E)16, papain-like protease (PDB: 
6W9C)17, and RNA-dependent RNA polymerase (PDB: 
7BTf)18 were obtained from the Research Collaboratory 
for Structural Bioinformatics (RCSB) database PDB 
(https://www.rcsb.org/)19.
2.2 Evaluation of ADMET Properties and Drug-
likeness 
The test for ADMET properties and drug-likeness of 
phytoligands based on Lipinski’s rule was performed using 
ADMETsar20 and SwissADME21. The predicted toxicity profile 
of all phytoligands and the control drugs were also determined 
using the PROTOX platform22.
2.3 Molecular Docking and Visualisation
Molecular docking of selected phytoligands and 
repurposing drugs with the targeted proteins were carried 
out and visualised using Hex 8.0.0 docking software23. The 
best docking site was considered using the binding free 
energies (high negative value). Hex uses spherical polar 
fourier (SPf) correlations. The docking was performed 
by adjusting appropriate parameters like correlation type- 
shape+electrostatics, ffT mode-3D, grid dimension-0.6, 
receptor range-180, ligand range-180, twist range-360, and 
distance range-40. The resultant binding energies (kJ/mol) were 
further tabulated24-25. The docked structures were visualised 
using The PyMOL Molecular Graphics System, Version 2.0 
Schrödinger, LLC (https://pymol.org/2/).  
2.4 Protein-ligand Interaction Study 
The interaction study of the targeted proteins with the 
selected phytololigands and repurposing drugs was carried 
out using the LIGPLOT program of Ligplot+ suite (Verion 
v.2.2)26-27. 
2.5 Conserved Domain Search
The conserved domains of the four viral proteins were 
retrieved using the conserved domain database (CDD), which 
were the source of protein annotation of NCBI Entrez query 
and retrieval system (https://www.ncbi. nlm.nih.gov/ Structure/
cdd/wrpsb.cgi).
2.6 Active Site Identification
The probable active sites or binding pockets of the four 
viral proteins were identified with CASTp28. The active sites 
were identified to find out whether the phytoligands and 
repurposing synthetic drugs are allosteric, orthosteric or bitopic 
in nature. 
3.  RESULTS
3.1 ADMET Properties and Drug-likeness
The ADMET properties and drug-likeness profile of the 
55 phytoligands and 8 repurposing synthetic drugs have been 
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depicted in Table 1. All phytoligands and repurposing drugs 
under the investigation were found to have suitable ADMET 
values and satisfy the suitable drug-likeness properties.
3.2 Molecular Docking Analysis
The binding energy values (E-total) of 55 phytoligands 
against SARS-CoV-2 spike glycoprotein (6VyB) were 
ranged between −102.51 kJ/mol (tyrosol) to −544.15 kJ/mol 
(colchicine) and that of repurposing synthetic drugs were 
ranged between −201.03 kJ/mol (favipiravir) to −846.66 kJ/
mol (saquinavir). The E-total values of 55 phytoligands 
against SARS-CoV-2 main protease 
(6Y2E) were ranged between −157.57 
kJ/mol (tyrosol) to − 712.63 kJ/mol 
(colchicine) and that of repurposing 
drugs were ranged between − 129.38 
kJ/mol (favipiravir) to − 1120.70 kJ/
mol (saquinavir). The binding energy 
values of 55 phytoligands against 
SARS-CoV-2 papain-like protease 
(6W9C) were ranged between −137.61 
kJ/mol (tyrosol) to −346.54 kJ/mol 
(oleic acid) and that of repurposing 
drugs were ranged between −198.21 
kJ/mol (favipiravir) to −323.32 kJ/
mol (nelfinavir). The binding energy 
values of 55 phytoligands against 
SARS-CoV-2 RNA-dependent RNA 
polymerase (7BTf) were ranged 
between −144.68 kJ/mol (tyrosol) 
to −627.24 kJ/mol (oleic acid) and 
that of repurposing synthetic drugs 
were ranged between −266.50 kJ/
mol (favipiravir) to −1100.66 kJ/mol 
(saquinavir). 
Authors determined a specific 
threshold limit of binding energy 
(E-total) concerning higher negative 
value for the final selection of 
phytoligands and repurposing synthetic 
drugs because the high negative value 
is required for better binding stability 
which may have better potential to 
develop anti-COVID-19 prophylaxis 
and therapy. The threshold binding 
energy of 55 phytoligands against 
spike glycoprotein, main protease, 
papain-like protease, and RNA-
dependent RNA polymerase of SARS-
CoV-2 were > −400 kJ/mol,  > −500 
kJ/mol, > −250 kJ/mol, and > −500 
kJ/mol, respectively. Similarly, the 
threshold binding energy values of 
8 repurposing drugs against spike 
glycoprotein, main protease, papain-
like protease, and RNA-dependent 
RNA polymerase were > −400 kJ/
mol, > −400 kJ/mol, > −250 kJ/mol, 
> −500 kJ/mol, respectively. Seventeen phytoligands and 7 
repurposing synthetic drugs showed optimum binding affinities 
against the viral proteins above these threshold limits. These 
17 phytoligands were andrographolide, apigenin, artemisinin, 
berberine, capsaicin, colchicine, emodin, glabridin, harmaline, 
harmine, kaempferol, niranthin, oleic acid, phyllanthin, rosavin, 
withaferin A,  and withanolide A; and those of 7 repurposing 
synthetic drugs were azithromycin, chloromethyl ketone, 
chloroquine, hydroxychloroquine, nelfinavir, remdesivir, and 
saquinavir. The docked complexes of the four viral proteins 
taken into consideration with their respective screened 
Figure 2. The minimum docked poses and corresponding Ligplot+ 2D interaction plot of 
repurposing synthetic drug saquinavir having the highest binding affinities with 
SARS-CoV-2 viral proteins. (a) spike glycoprotein (6VYB), (b) main protease 
(6Y2E), (c) papain-like protease (6W9C), (d) RNA-dependent RNA polymerase 
(7BTF).
Figure 1. The minimum docked poses and corresponding Ligplot+ 2D interaction plot of 
phytoligands having highest binding affinities with SARS-CoV-2 viral proteins. (a) 
spike glycoprotein (6VYB) vs colchicine, (b) main protease (6Y2E) vs colchicine, 
(c) papain-like protease (6W9C) vs oleic acid, (d) RNA-dependent RNA polymerase 
(7BTF) vs oleic acid.
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phytoligands and repurposing synthetic drugs having the 
highest binding affinities have been shown in Fig. 1-2.
3.3 Study of Protein-ligand Interaction 
The viral protein-phytoligand/repurposing drug 
interaction was performed using Ligplot+. The interactions 
of the screened phytoligands and repurposing drugs with 
the four viral proteins along with the detailed depiction 
of the amino acid residues involved in forming hydrogen 
bonds and hydrophobic interactions and the total number 
of hydrophobic interactions and hydrogen bonds of each 
ligand with respective protein has been shown in fig. 3. 
The information regarding the chain number and residue 
number were provided therein. The total number of hydrophobic 
interactions and hydrogen bonds for each of the screened 
phytoligands and synthetic drugs were graphically represented 
in figs. 3 (a) - 3(d). The number of hydrophobic interactions 
exceeded the number of hydrogen bonds in all cases. In case 
of spike glycoprotein, glutamine showed the maximum bias 
towards forming hydrogen bonds and hydrophobic interactions 
followed by glutamic acid, alanine, aspartic acid, and leucine. 
The least common residue involved was arginine. All other 
residues were resided in between (fig. 3(a)). Considering the 
main protease, there was threonine richness in bond formation 
followed by proline, asparagine, and glutamic acid. The least 
common residues for interaction and bond formation were 
tryptophan< valine< isoleucine< methionine (fig. 3(b)). for 
papain-like protease, there was tyrosine bias in hydrophobic 
interactions followed by proline, asparagine, 
and glutamic acid. However, in this case, 
the hydrogen bond formation showed a bias 
towards glutamic acid, followed by threonine, 
proline, and asparagine. Cysteine was the least 
involved residue for any kind of interface (fig. 
3(c)). for RNA-dependent RNA polymerase, 
glutamic acid richness was found in the 
interactions. Overall, the number of hydrogen 
bond formation, here, was less as compared to 
the three other viral proteins. Glutamic acid 
bias was followed by aspartic acid, alanine, 
threonine, and tryptophan. Glutamine was the 
least biased residue in forming interfaces in 
the case of RNA-dependent RNA polymerase 
(fig. 3(d)). In all the four viral proteins taken 
into consideration, the results showed a 
commonality in glutamic acid bias towards 
forming interactions with selected phytoligands 
and repurposing synthetic drugs. 
3.4  Active Site Analysis
Among the binding pockets evaluated by 
CASTp for the viral proteins, only the largest 
pocket for each protein was considered. The 
probe radius used for pocket identification 
was 1.4Å as shown in fig. 4. The amino acids 
present in the probable active sites of all the 
four viral proteins were compared with the 
amino acid residues docked with the proteins 
in the results obtained from LIGPLOT. 
It was found that out of the 55 phytoligands 
and 8 repurposing synthetic drugs, some 
showed allosteric properties while few other 
showed orthosteric features. Interestingly, 
few ligands also showed bitopic properties. 
As, in our study, the screening of 17 out of 
55 phytoligands and 7 out of 8 repurposing 
synthetic drugs were mainly based on their 
binding affinities toward respective viral 
proteins, the binding properties (whether 
orthosteric, allosteric or bitopic) of these 24 
ligands were primarily taken into consideration. 
We found that most of the phytoligands 
Figure 3. Hydrogen bonds and hydrobhobic interactions of SARS-CoV-2 proteins 
with phytoligands and repurposing drugs. (a) spike glycoprotein (6VYB), 
(b) main protease (6Y2E), (c) papain-like protease (6W9C),  and (d) 
RNA-dependent RNA polymerase (7BTF).
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and repurposing drugs may act as allosteric or orthosteric 
or bitopic, depending upon the protein they were binding to 
(Fig. 5).  For example, artemisinin was orthosteric for spike 
glycoprotein, allosteric for main protease and papain-like 
protease, but it was acting as bitopic against RNA-dependent 
RNA polymerase. There were no allosteric phytoligands and 
repurposing synthetic drugs in case of spike glycoprotein.
4.   DISCUSSION
Similar to SARS and MERS β-coronaviruses, SARS-
CoV-2 is an enveloped, positive-sense, single-stranded 
RNA virus, but with a much higher rate of spreading 
efficiency than the other coronaviruses. We carried out this 
investigation to show the inhibitory potential of phytoligands 
and repurposing synthetic drugs in terms of binding affinity 
towards the spike glycoprotein (that helps the virus to attach 
with the host cell receptor and fuse with the cell membrane 
thereby facilitates the entry of viral genes to host cell to be 
copied, and viral multiplication), main protease 
(that helps in processing of the polyproteins 
translated from viral RNA to produce functional 
viral proteins), papain-like protease (proteolytic 
and deubiquitinating function, the de-ISGylating 
capacity of protein conjugates, and helps in viral 
evasion of the host innate immune responses), 
and RNA-dependent RNA polymerase (the central 
enzyme of viral replication), the most prominent 
antiviral targets of SARS-CoV-2. Targeting these 
viral proteins with antiviral molecules would be of 
great significance in not only inhibiting viral entry, 
processing of translated proteins, and replication 
but also restraining the dysregulation of cellular 
signaling events infected cells that might cause cell 
death in the adjacent, uninfected cells. from our 
results, it was evident that all 55 phytoligands and 
8 repurposing drugs showed inhibitory potential 
(binding affinity) against the viral proteins. The highest binding 
affinities of phytoligands towards the antiviral targets were 
shown by colchicine and oleic acid, and that of repurposing 
drugs were exhibited by saquinavir and nelfinavir. Especially, 
17 phyloligands viz. andrographolide, apigenin, artemisinin, 
berberine, capsaicin, colchicine, emodin, glabridin, harmaline, 
harmine, kaempferol, niranthin, oleic acid, phyllanthin, 
rosavin, withaferin A, withanolide A; and 7 repurposing drugs 
namely azithromycin, chloromethyl ketone, chloroquine, 
hydroxychloroquine, nelfinavir, remdesivir, and saquinavir 
showed significantly higher binding affinities towards the viral 
proteins. The positive ADMET properties and drug-likeness 
profile of all phytoligands under this investigation warrant their 
probable use for prophylactic and/or therapeutic interventions. 
We also determined 2 phytoligands (capsaicin and oleic acid) 
and 4 repurposing drugs (azithromycin, nelfinavir, remdesivir, 
and saquinavir) acting as broad-spectrum inhibitors against 
these antiviral targets putatively. Protein-ligand interaction 
Figure 5. Bar graph showing the binding properties (orthosteric, allosteric 
and bitopic) of phytoligands and repurposing synthetic drugs for 
SARS-CoV-2 proteins.
Figure 4. Putative active sites of SARS-CoV-2 proteins showing area and volume. (a) spike glycoprotein, (b) main protease, (c) 
papain-like protease, and (d) RNA-dependent RNA polymerase. 
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Figure 6. Specific and broad-spectrum phytoligands and repurposing synthetic drugs with higher binding energy (E-total) against 
the four antiviral targets under investigation.
data showed significant variation in the number of hydrogen 
bonds and hydrophobic interactions of amino acid residues 
that are included within the conserved domain along with 
commonality in glutamic acid richness towards forming 
interactions of all viral proteins with selected phytoligands and 
repurposing synthetic drugs. 
Any known prophylaxis, therapeutic intervention, and 
vaccine candidates against COVID-19 are still unavailable. 
Several clinical therapies were approved and are at full swing 
following various approaches such as repurposing anti-
influenza and anti-retroviral drug candidates with different 
combinations, immunomodulation and/or immunosuppression-
derived therapeutic intervention, combinational plasma 
therapy, monoclonal antibody treatment, etc. for the treatment 
of COVID-1929-32. However, these medications were found to 
produce a negative outcome and very less number of patient 
recoveries due to the severe complications and side effects 
associated with these therapies and drug candidates, which 
lead to increased mortality across the globe33-34. 
Medicinal plants have achieved increased attention among 
researchers and medical practitioners all over the world for 
its enormous therapeutic and health-promoting properties. At 
the turn of twenty-first century, scientists and pharmacologists 
around the globe have put great efforts to discover the most 
efficient and safe phytomedicines against various health 
ailments using different botanical resources. Various Indian 
medicinal plants were reported to possess antiviral properties, 
but their pharmacological validations remain to be explored 
with detail12. The Indian context of the healthcare system in 
particular is also comprised of various ethnobotanical and/or 
traditional knowledge-based components such as Ayurveda, 
Unani, Siddha, Sowa-Rigpa, etc. However, very few 
research investigations have been conducted to validate the 
pharmacological efficacy, mechanism of action, and safety 
profile of these phytomedicines9-12. Conducting in vivo trials 
using animal models and human volunteers to validate the 
efficacy of diverse bioactive ingredients from natural sources 
require huge investment, ethical constrain, and extended 
time. Therefore, virtual screening of active ingredients, 
prediction of drug-likeness, pharmacological efficacy, and 
specificity of botanical active principles with computational 
tools would be of great significance for discovering novel 
phytomedicines. The repurposing drugs were also found 
to be partially successful in a small number of cases due 
to a lack of specificity and efficacy against SARS-Cov-2. 
The development of an efficient vaccine against this virus 
having a high frequency of mutation, the peculiar mode of 
infection, and multi-factorial damage to its host would be a 
herculean task for the scientists all over the globe. Therefore, 
the discovery of prophylaxis with optimum efficacy against 
SARS-Cov-2 would be great hope to combat the disease. 
Development of combination therapies using synthetic drugs 
and potential anti-SARS-Cov-2 phytoligands would not only 
provide higher synergistic action but also lower the severity 
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of side effects caused by the repurposing antiviral therapies 
and pave the way of discovering novel prophylaxis and 
therapeutic intervention against COVID-19.
We observed significant variation of binding affinities in 
different phytoligands and repurposing drugs targeted against 
the 4 antiviral targets. Based on the ADMET properties, 
binding energy, and protein-ligand interaction profile, we 
finally identified the plausible 17 potent phytoligands viz. 
andrographolide, apigenin, artemisinin, berberine, capsaicin, 
colchicine, emodin, glabridin, harmaline, harmine, kaempferol, 
niranthin, oleic acid, phyllanthin, rosavin, withaferin A, and 
withanolide A to inhibit the 4 viral proteins studied under this 
investigation. On the other hand, the 7 repurposing synthetic 
drugs viz. azithromycin, chloromethyl ketone, chloroquine, 
hydroxychloroquine, nelfinavir, remdesivir, and saquinavir 
showed optimum antiviral properties by inhibition of 4 viral 
components under investigation (fig. 6). from these results, 
we also identified the putative specific and broad-spectrum 
phytoligands and repurposing synthetic drugs acting against 
the 4 antiviral targets under investigation (fig. 6). Among all 
phytoligands, oleic acid and capsaicin were found to exhibit 
broad-spectrum binding affinity towards these antiviral targets 
of SARS-CoV-2. Among the repurposing drugs, saquinavir, 
nelfinavir, azithromycin, remdesivir showed broad-spectrum 
binding affinity towards all antiviral targets. Four phytoligands 
such as colchicine, berberine, andrographolide, and artemisinin 
along with one repurposing drug chloroquine were also found 
to possess potential binding affinities towards 3 antiviral targets 
except for papain-like protease. The phytoligand apigenin was 
found to have an optimum binding affinity towards the spike 
glycoprotein and the main protease of SARS-CoV-2 (fig. 6).
Colchicine showed the highest binding energy of −544.15 
kJ/mol and −712.63 kJ/mol against the spike glycoprotein 
(6VyB) and main protease (6y2E), respectively. Oleic acid 
exhibited the maximum binding affinity with −346.54 kJ/mol 
and −627.24 kJ/mol, against papain-like protease (6W9C) 
and RNA-dependent RNA polymerase (7BTf), respectively. 
Among the repurposing drugs under investigation, saquinavir 
showed the highest binding energy of −846.66 kJ/mol, 
−1120.70 kJ/mol, −323.32 kJ/mol, and −1100.66 kJ/mol against 
spike glycoprotein (6VyB), main protease (6y2E), papain-
like protease (6W9C) and RNA-dependent RNA polymerase 
(7BTf), respectively. Our results were in corroboration with 
previous reports where saquinavir was found to produce 
optimum inhibition against viral main protease35.
The overall interaction data indicated that both the 
phytoligands and the repurposing synthetic drugs rely more on 
hydrophobic interactions for binding with the target proteins 
as compared to hydrogen bonds. The bias towards some amino 
acids may indicate some distinctive patterns. The glutamic acid 
bias in the interfaces helps us to conclude that glutamic acid-rich 
interactions possibly will lead to viral protein solubility change 
that in turn may affect the viral lethality towards the host36. We 
also found aspartic acid richness. Aspartic acid is important 
in proper receptor functioning that in turn may stabilise the 
protein-ligand complexes37. The bias towards glutamine in the 
case of spike glycoprotein-ligand/synthetic drug interaction 
may increase the stability of the complexes38. Tyrosine bias in 
papain-like protease was observed. Tyrosine was also found 
to facilitate molecular interactions and may affect the binding 
affinity and specificity39. Threonine is also essential for viral 
assembly and stability40. We observed threonine richness 
primarily in main protease-ligand/repurposing drug interaction 
and also more or less in the case of the other three viral proteins. 
These interactions, thus, may affect the normal viral structural 
conformation and also their activities.
Conserved domain analysis of viral proteins revealed the 
following findings. For spike glycoprotein, the phytoligands 
and repurposing drugs interacted with the residues that were 
included within the Corona_S2 superfamily conserved domain. 
A similar observation was found for the main protease. The 
conserved domain betaCoV_Nsp5_Mpro was in the interval 
of 4-300 and all the residues that interacted with the respective 
ligands were within this range. Viral_protease superfamily 
of papain-like protease was within the interval of 1-315. 
The residues within these intervals were involved in protein-
ligand interaction. for RNA-dependent RNA polymerase, 
the SARS-CoV-like_RdRp (interval 5-932), the same results 
were concluded as above. These results may help us to get 
insights into the functional pattern of the conserved domains 
with and without drug interactions.  further characterisation 
of the interaction of the SARS-Cov-2 protein domains with 
phytoligands and repurposing synthetic drugs may help in drug 
target identification.
Andrographolide, apigenin, artemisinin, berberine, 
capsaicin, emodin, harmine, harmaline, kaempferol, and oleic 
acid, were found to produce therapeutic action against zoonotic 
respiratory viral threats such as H1N1, H9N2, H5N1, H3N2, 
and SARS coronaviruses which may be effective against the 
new and emerging infectious disease like COVID-1941-44. 
Our results were in agreement with previous report where the 
plausible anti-SARS-CoV-2 potential of lipid-soluble alkaloid 
colchicine was recommended and under clinical trial for the 
prevention of cytokine storm and fibrosis in COVID-19 due to 
its anti-inflammatory and anti-fibrotic properties45. Bioactive 
lipid, like oleic acid and other botanical active ingredients like 
emodin, harmine, and harmaline was also hypothesised to be 
the potent lead molecules for anti-COVID drug development46. 
Along with capsaicin and oleic acid, which were associated 
with high binding affinities towards the 4 SARS-CoV-2 
antiviral targets, few other phytoligands namely glabridin, 
niranthin, phyllanthin, rosavin, withaferin A, and withanolide 
A were also found to show potential inhibition against 
papain-like protease of SARS-CoV-2. Glabridin, niranthin, 
phyllanthin, rosavin, withaferin A, and withanolide A have 
been reported for their antiviral properties and may have 
the potential to inhibit the antiviral targets of SARS-CoV-2 
with high specificity and efficiency11,47. However, validation 
of the pharmacological efficacy of these 17 phytoligands 
showing higher binding affinity and residue interaction (Fig. 6) 
against the potential antiviral targets of SARS-CoV-2 are yet 
to be explored with detail. Therefore, the in vivo inhibitory 
potential of these phytoligands along with repurposing drugs 
with various combinations should be tested against COVID-19 
which may produce improved synergistic effect.
Similar approach was followed by previous investigators 
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from different parts of the globe to discover potential repurposing 
drugs and phytomolecules against SARS-CoV-2 by virtual 
screening and computational methods4,32,48-50. However, no data 
is available to date to show the inhibitory potential of broad-
spectrum phytoligands and repurposing synthetic antiviral 
drugs which might be effective against the 4 prime antiviral 
targets of SARS-CoV-2 included in our study. We carried 
out this investigation with SARS-CoV-2 protein structures 
retrieved RSCB PDB which were recently resolved by electron 
microscopy and X-ray diffraction. However, in contrast 
with our study, most of the previous research investigators 
showed the in silico inhibitory potential of phytomolecules 
against homology-based predicted structures of SARS-CoV-2 
proteins which may not hold conclusive remarks. Also, very 
less information is available to demonstrate the insight of 
protein-ligand interaction profile and its relation to developing 
possible inhibitors against SARS-CoV-2 viral proteins studied 
in this investigation. Therefore, to the best of our knowledge, 
this is the first study to demonstrate the in-depth protein-
ligand interaction profile of SARS-CoV-2 viral proteins and 
phytoligands/repurposing synthetic drugs to discover the 
plausible specific and broad-spectrum novel phytomedicne or 
prophylactic against COVID-19.
In the present study, the phytoligands and repurposing 
drugs showed differential binding properties such as orthosteric, 
allosteric or bitopic functions against SARS-CoV-2 viral 
proteins. Orthosteric drugs binds to the active site of the target 
protein while allosteric drugs are binds to the protein surface 
other than the active site. Orthosteric drugs act by blocking the 
active site so that the native substrate becomes unable to bind to 
it. Conversely, allosteric drugs result in conformational change 
in the protein structure that in turn affects protein activity. 
Allosteric drugs, thus, are able to modify the protein activity 
unlike orthosteric drugs that focus on blocking the active site. 
The drugs available to us are commonly orthosteric. But, there 
are some disadvantages of orthosteric drugs. As they bind to 
the active site of the target protein, there are probabilities that 
they may also bind to other homologous proteins or proteins 
that belong to the same family as active sites are highly 
conserved. On the other hand, as allosteric drugs bind to the 
protein surfaces, which are much less conserved compared 
to the active site and non-competitive to endogenous ligands; 
hence, even if the target protein is bound to an endogenous 
ligand, allosteric drugs can be influential to the target protein 
by modulating its activity51. 
Several studies revealed that allosteric drugs have lesser 
side effects as compared to orthosteric drugs. Nevertheless, 
orthosteric drugs have many advantages, mainly, as they 
directly target the active site and hence, influence protein 
activity in a much faster way and stop it entirely.  Mostly, the 
drugs available are categorised into these two types, but there 
is a new class of ligand, called bitopic ligands that have dual 
characteristic features, that is they can bind to both orthosteric 
as well as allosteric sites of the same protein at the same time52. 
Till date, the studies were mostly inclined towards designing 
of allosteric drugs or bitopic drugs. Hence, a combinatorial 
approach of applying multidrug therapy towards a target 
protein may open new avenues in drug discovery.
As, authors screening of 17 phytoligands and 7 
repurposing synthetic drugs was based on their binding 
energies while docking with the viral proteins, the binding 
properties (orthosteric, allosteric or bitopic) of these ligands 
were mainly focussed on. Artemisinin, berberine, capsaicin, 
colchicine, emodin, harmaline, harmine, niranthin, rosavin 
among phytoligands and azithromycin, chloromethyl ketone 
and remdesivir among repurposing drugs were found to 
show all three types of binding properties (i.e. orthosteric, 
allosteric or bitopic). Bitopic and allosteric properties 
were shown by andrographolide, apigenin, kaempeferol 
phytoligands and hydroxychloroquine, nelfinavir, 
saquinavir repurposing drugs. Glabridin, withaferin A and 
withanolide A were found to exhibit orthosteric as well as 
bitopic properties. Oleic acid exhibited both allosteric and 
bitopic properties whreas phyllanthin showed orthosteric 
and allosteric properties. 
In authors investigation, most of the selected ligands 
exhibited all the three types of binding properties. In 
recent time, drug discovery research focused on modifying 
orthosteric drugs into allosteric drugs and vice versa and 
also orthosteric and allosteric ligands into bitopic one. 
from our study, the ligands under investigation could 
be effective as orthosteric, allosteric or bitopic drugs. 
Depending upon the binding energies of the ligand-viral 
proteins docked complexes along with considering their 
nature of binding properties viz. orthosteric, allosteric or 
bitopic, a multi-drug therapy combinatorial approach may 
prove phenomenal in fighting against SARS-CoV-2. In this 
context, we need to select those drugs that will have the 
strongest binding energies with least side effects and fast 
approach towards deactivating protein functions. Our study 
is plausibly the first of its kind in reporting the multi-drug 
therapy against SARS-CoV-2 based upon binding energies 
and binding properties. This approach may provide a novel 
strategy against this deadly virus and possibly will solve 
the problem of drug resistance and can become a prodigious 
approach for next generation pharmacology.
In recent time, few clinical trials have already been 
approved and set in motion with medicinal plants to develop 
anti-COVID-19 phytomedicines and prophylaxis8. However, 
the anti-SARS-CoV-2 inhibitory properties of Indian medicinal 
plants still remain to be investigated with details. To the best 
of our knowledge, this is the first report where we showed the 
antiviral potential of these phytoligands obtained from widely 
available botanical resources against the 4 major SARS-CoV-2 
proteins like spike glycoprotein, main protease, papain-like 
protease, and RNA-dependent RNA polymerase. Especially, 
the 17 potential phyloligands found in the common and 
traditionally used medicinal plants with promising ADMET 
properties and prominent inhibitory action against the most 
significant antiviral targets, if utilised in combination with 
the synthetic repurposing medicines such as azithromycin, 
chloromethyl ketone, chloroquine, hydroxychloroquine, 
nelfinavir, remdesivir, saquinavir, etc. may provide improved 
synergistic effect and novel lead for developing alternative 
therapy against COVID-19 until the discovery of a successful 
vaccine against the virus. Therefore, our results will definitely 
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provide new avenues to explore the plausible anti-SARS-
CoV-2 potential of bioactive ingredients from the widely 
available plant sources.
5.  CONCLUSIONS
Out of 55 phytoligands under investigation, 17 
phytoligands viz. andrographolide, apigenin, artemisinin, 
berberine, capsaicin, colchicine, emodin, glabridin, harmaline, 
harmine, kaempferol, niranthin, oleic acid, phyllanthin, rosavin, 
withaferin A, and withanolide A showed optimum inhibitory 
potential in terms of higher binding affinities and interactions 
with the antiviral targets namely spike glycoprotein (6VyB), 
main protease (6y2E), papain-like protease (6W9C), and 
RNA-dependent RNA polymerase (7BTf) of SARS-CoV-2. 
On the other hand, out of 8 repurposing synthetic drugs, 7 
drug candidates namely azithromycin, chloromethyl ketone, 
chloroquine, hydroxychloroquine, nelfinavir, remdesivir, and 
saquinavir exhibited higher binding affinities and interactions 
against these antiviral targets. Hence, these molecules could 
prevent the attachment, replication, and processing of SARS-
CoV-2 viral particles within the host cell. Therefore, these 
phytoligands along with synthetic drugs should be studied 
in different combinations to obtain the optimum antiviral 
synergistic effect in cell-based assays, animal systems, and 
clinical trials which may lead to the discovery of novel, safe, 
and affordable phytomedicine and/or prophylactic therapy 
with highest efficiency and specificity. In the process of finding 
solutions to the pandemic crisis, we are taking notes of the 
most abundant natural sources. In such a time, initiatives must 
be taken constantly to find ways from the common medicinal 
plants around us. With heightened senses, we have begun 
discovering antiviral pharmaceutical ingredients from quality 
raw materials and ensure that these active ingredients should 
act with optimum specificity and efficacy against SARS-
CoV-2. 
It is obvious to our vision that to settle the figuring, 
production, and generation of medicinal plants as the layer of 
our existence. At a stretch, it will open a new guideline and 
edge to the tedious pharma industry. So, this investigation may 
bring new hope of drug discovery by showing the plausible 
utilisation of widely available phytoligands with long lines of 
medicinal plants and safe repurposing drugs in combination 
against COVID-19. The extension of thrust to the usage of 
medicinal plants has been seemingly pointed out the length 
of safety, empowerment, and industrial application that could 
supply objectivity to any pandemic crisis.
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